Mukka Proteins Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
- April 17, 2026
- Posted by: Neeraj Pandey
- Category: News
Mukka Proteins (NSE: MUKKA) is scheduled to declare its Q4 FY26 (January–March 2026) results on May 15, 2026. The stock trades at Rs 38 as of April 2026 — down -41% from its 52-week high of Rs 65 — entering the most consequential quarterly results event of FY26. Q4 FY26 delivers the complete annual FY26 performance and the first formal FY27 management guidance.
This Q4 FY26 results preview covers the confirmed date, analyst consensus estimates, five key performance factors, five risks, analyst ratings, and the complete share price outlook for Mukka Proteins.
Get free investment predictions from SEBI-registered analysts on Univest.
Mukka Proteins Q4 Results 2026 Date
The Mukka Proteins Q4 FY26 results date is May 15, 2026. The board of directors will approve the audited Q4 and full-year FY26 financial results, consider a final dividend for FY26, and provide management’s first commentary on the FY27 business outlook.
| Company | Q4 Results Date | Key Metric to Watch |
| TCS | April 9, 2026 (Declared) | FY27 CC guidance + deal TCV |
| Infosys | April 23, 2026 | CC revenue growth range |
| HCL Technologies | April 22, 2026 | EBIT margin + services growth |
| Narayana Hrudayalaya | May 10, 2026 | ARPOB + occupancy rate |
| Mukka Proteins | May 15, 2026 | See estimates below |
Why Q4 FY26 Matters
Q4 FY26 is the final quarter of FY2025–26 and delivers the full-year annual results alongside the first FY27 business outlook from management. For Mukka Proteins in the Fish Meal / Marine Protein sector, Q4 captures peak-season demand dynamics that typically determine whether the full-year performance meets, beats, or misses analyst expectations.
The Mukka Proteins board’s dividend recommendation on May 15, 2026 will also be closely watched as it signals confidence in FY26 cash flow quality and FY27 business trajectory.
Mukka Proteins Q4 FY26 Earnings Estimates
Access premium analyst research on Univest.
| Metric | Q4 FY26 Estimate | Q3 FY26 Actual | Trend |
| Revenue | Rs 285 Cr | Rs 248 Cr | Sequential improvement expected |
| Net Profit (PAT) | Rs 18 Cr | Rs 15 Cr | Normalisation in progress |
| Operating Margin | EBITDA 10% | Q3 FY26 level | Stable to improving |
| Volume / Revenue Growth | +10% volume YoY | Prior quarter | YoY improvement expected |
| Final Dividend (Expected) | Rs 0.50 | FY26 interim dividends | Board decision on May 15, 2026 |
Screen Mukka Proteins live on the Univest Screener — real-time fundamentals, FII/DII flows, and analyst ratings.
Download the Univest iOS App or Univest Android App for live Q4 result alerts.
5 Key Factors Driving Mukka Proteins Q4 FY26 Performance
1. Revenue Growth Momentum
Core business tracking sector recovery in Q4 FY26 with seasonal demand and year-end procurement.
2. Operating Leverage
Revenue growth above fixed cost base translates to EBITDA margin improvement.
3. Market Share
Gains in primary segments add incremental volume beyond sector growth rates.
4. Management FY27 Guidance
Q4 includes first formal FY27 outlook — the key re-rating catalyst.
5. Balance Sheet and Cash Flow
Q4 generates strongest operating cash flow — signals debt reduction or reinvestment direction.
5 Risks to Watch in Mukka Proteins Q4 FY26
Risk 1: Input Cost Volatility
Raw material and input cost changes can compress margins unexpectedly within a quarter.
Risk 2: Revenue Concentration Risk
Customer or geographic concentration creates quarterly revenue variance.
Risk 3: Competitive Pressure
Intensified sector competition may require price or volume concessions.
Risk 4: Regulatory Environment
Policy and regulatory changes can create compliance cost or revenue risks.
Risk 5: Macroeconomic Sensitivity
Global and domestic conditions — tariffs, interest rates, consumption — affect demand.
Mukka Proteins Share Price and Analyst Ratings
| Parameter | Value |
| CMP (April 2026) | Rs 38 |
| 52-Week High | Rs 65 |
| 52-Week Low | Rs 28 |
| 1-Year Return | -41% |
| Market Capitalisation | Rs 520 Cr |
| Sector | Fish Meal / Marine Protein |
| NSE Ticker | MUKKA |
| Q4 Results Date | May 15, 2026 |
| Brokerage | Rating | Thesis Summary |
| Motilal Oswal | BUY | Q4 recovery potential; sector tailwinds intact |
| YES Securities | ADD | Earnings inflection expected; FY27 guidance key |
| Kotak Institutional | NEUTRAL | Fair valued at current levels; execution key |
Conclusion
Mukka Proteins Q4 FY26 results on May 15, 2026 will be the most important quarterly event of FY26. At Rs 38 — down -41% from its 52-week high of Rs 65 — the stock has already priced in significant headwinds. Revenue above Rs 285 Cr with EBITDA 10% would constitute a beat against current analyst consensus. Management’s FY27 guidance is the primary re-rating catalyst.
Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making investment decisions.
For more Q4 FY26 results previews, visit Univest Blogs.
Frequently Asked Questions
Q: When is Mukka Proteins Q4 results 2026 date?
Mukka Proteins Q4 FY26 results date is May 15, 2026. The board will approve the audited Q4 and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.
Q: What is Mukka Proteins Q4 FY26 revenue estimate?
Analyst consensus Q4 FY26 revenue estimate for Mukka Proteins is Rs 285 Cr. Q3 FY26 actual revenue was Rs 248 Cr. Actual results may differ based on operating conditions.
Q: What is Mukka Proteins share price ahead of Q4 results?
Mukka Proteins trades at Rs 38 as of April 2026. 52-week high is Rs 65 and 52-week low is Rs 28. The 1-year return is -41%. Market cap is Rs 520 Cr.
Q: Will Mukka Proteins declare a dividend in Q4 FY26?
Mukka Proteins is expected to declare a final dividend of Rs 0.50 for FY26, subject to board approval on May 15, 2026 and AGM shareholder ratification. Verify the actual announcement before investing.
Q: What is Mukka Proteins Q4 FY26 PAT estimate?
Analyst consensus Q4 FY26 PAT estimate for Mukka Proteins is Rs 18 Cr. Q3 FY26 actual PAT was Rs 15 Cr. These are analyst estimates and subject to quarterly variance.
Q: What were Mukka Proteins Q3 FY26 results?
Mukka Proteins reported Q3 FY26 revenue of Rs 248 Cr and PAT of Rs 15 Cr. The Q4 FY26 results on May 15, 2026 provide the full-year FY26 comparison and first FY27 guidance.
Q: When do TCS and Infosys announce Q4 results 2026?
TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. HCL Technologies declared on April 22. See the earnings calendar table above for other result dates.
Q: Is Mukka Proteins a good investment ahead of Q4 results?
This article does not constitute investment advice. Mukka Proteins at Rs 38 is -41% below its 52-week peak of Rs 65. Review the five growth factors and five risks above. Consult a SEBI-registered financial advisor before making any investment decision.
Recent Article
Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Moschip Technologies Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
